Why GPCRs

Around a third of approved drugs act on GPCRs, almost all of them small molecules. Antibodies offer what small molecules often cannot: precise selectivity between closely related receptors, long dosing intervals and engineerable formats such as bispecifics. They have been hard to make because GPCRs expose only small, flexible surfaces outside the cell and are difficult to produce in their native form for immunization and screening.

RedQueen™, our discovery engine

RedQueen™ is the proprietary platform we built to create our pipeline. It reproduces affinity maturation – the immune system’s way of improving antibodies – in silico. Populations of antibody variants are mutated, scored with physics-based models of the antibody–receptor interface and selected over many generations, with AI used to prioritize candidates. Developability and manufacturability are assessed alongside affinity from the first design round.

Validated in the lab

Every candidate is synthesized and tested: binding by bio-layer interferometry or cell-based, expression in CHO cells and activity in functional cell-based assays. In 2026, RedQueen™ designed antibodies showed nanomolar binding to native receptors for two high-value GPCR targets, and moved into functional characterization.

What this means for our pipeline 

• Speed: design cycles measured in weeks rather than months. 

• Breadth: our first campaign covered about 30 targets and more than 100,000 candidates, so we choose programs from a wide funnel. 

• Access: we design against defined epitopes and receptor states that immunization and library screening rarely reach.